12th Biosimilars Congregation

12th Biosimilars Congregation is organized by Virtue Insight and will be held during Feb 27 - 28, 2018 at Holiday Inn London - Kensington High St, London, England, United Kingdom.

The target audience for this medical event is CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles of Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins/Biosimilars, Biologics/Biotechnology/ Biogenerics, Legal Affairs, Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affairs, Marketing.

Conference Description :
Our 12th Biosimilars Congregation 2018 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe, Biosimilar products to the market place. By attending this conference, you will gain a comprehensive outlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

The Biosimilars market is going to heat up considerably over the next three years. Biosimilar versions of a number of major biologic drugs used in the treatment of cancers and rheumatic diseases are expected to complete their development and potentially come on to the market. In order to ensure the sustainability of public healthcare systems, in the context of aging populations and the growing number of diagnosed chronic diseases, it will be essential to harness the potential of Biosimilars to deliver savings, so that greater numbers of patients can be treated with these medicines.

Conference Themes are :
• Strategies for market access and expansion by identifying key changes and future projections in biosimilars
• Brexit and Biosimilars.
• Current market trends and future challenges for Biosimilar success.
• A Clinicians Guide to Biosimilars in Oncology: understanding the Science of Extrapolation and Interchangeability.
• Current challenges and opportunities - strategies to develop Biosimilars.
• Payer perspective on biológics and Biosimilars.
• Biosimilar Interchangeability: The newest regulation.
• Biosimilar, biobetter and next-generation therapeutic antibodies.
• Guidance on interchangeability laws, patient litigation and IP rules.
• CMC, Preclinical and clinical considerations for Biosimilars and Follow-on Biologics.
• Impact of Technology.
• Know the challenges of Biosimilar manufacturing.
• Gain in-depth knowledge on role of technology transfer - How does this effect market access?
• Biosimilars development and impact on clinical practice.
• Hear case studies on biosimilars drug development from pre-clinical to clinical and the various testing required such as immunogenicity and bio-similarity tests.
• Production of biosimilar MAbs.
• Research-based industry Biosimilar strategies.
• Considerations for the analytical similarity assessments when designing a Biosimilar development program.
• Determining the right investments & potential returns from Biosimilars.
• Latest developments in regulation to increase speed of entry and compliance.
• Future of next-generation biosimilars.
• Be part of a major networking opportunity.